DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

Calithera Biosciences reported that the company’s CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.

Less than a month after the failure of a Phase III Duchenne muscular dystrophy (DMD) trial, Switzerland-based Santhera Pharmaceuticals announced a corporate restructuring that includes the termination of 50 percent of the company’s workforce.

Shares of Bellicum Pharmaceuticals plunged following an announcement that the company will slash 79% of employees as part of a restructuring following the developmental pause for one CAR-T program.

France’s Genfit announced significant restructuring that will include cutting 40 percent of the company’s staff.

Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).

San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.

Genentech is eliminating 474 employees, mostly based out of the company’s South San Francisco facilities, with the job cuts expected to be permanent.

DBV Technologies is cutting jobs while awaiting news from the U.S. Food and Drug Administration about the company’s approval application for Viaskin Peanut.

Lundbeck is making changes to the global pharma company’s R&D initiative, which could lead to a reduction of up to 160 positions.